1. Scrip
  3. >>Anti-infective

Former Dendreon CEO Gold's New Cell Therapy Business Partners With Kite

 
• By Mandy Jackson

With insights into what's needed to make a cell therapy for cancer succeed, former Dendreon Corp. CEO Mitchell Gold is shepherding new technology for closely-watched immunotherapies into the clinic through his latest company Alpine Immune Sciences Inc., which has entered into a $535m-plus partnership with Kite Pharma Inc.

With insights into what's needed to make a cell therapy for cancer succeed, former Dendreon Corp. CEO Mitchell Gold is shepherding new technology for closely-watched immunotherapies into the clinic through his latest company Alpine Immune Sciences Inc., which has entered into a $535m-plus partnership with Kite Pharma Inc.

Cell therapy developers learned a lot from Dendreon's experience with the hotly-anticipated immunotherapy Provenge (sipuleucel-T), which didn't live up to its blockbuster expectations once the autologous cell therapy entered the commercial market

More from Anti-infective

More from Therapy Areas

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.